ClinicalTrials.gg
RecruitingNCT07854223Updated Oct 2, 2026

Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill Run

An interventional study of Caffeine and L-Citrulline in Exercise Physiology and Nutritional Supplementation, sponsored by St. Louis University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by St. Louis University · Not applicable, Interventional, and Basic science

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This study will examine how three commonly used pre-run nutritional supplements-caffeine, L-citrulline, and an exogenous ketone supplement-affect physiological and perceptual responses during a fixed-pace 5 km treadmill run in healthy, physically active runners.

Participants will complete one screening and baseline visit followed by four experimental visits in a randomized order. At each experimental visit, participants will receive caffeine, L-citrulline, an exogenous ketone supplement, or placebo before completing a fixed-pace 5 km treadmill run. Each participant will receive all four conditions and will therefore serve as their own control.

The study will evaluate measures including running economy, heart-rate responses, oxygen consumption, respiratory measures, blood lactate and ketone concentrations, perceived exertion, gastrointestinal symptoms, fatigue, energy, and focus. A randomly selected subgroup will also wear a continuous glucose monitor to explore glucose responses during the experimental visits. The study will also assess the feasibility and tolerability of completing repeated treadmill trials under the four supplement conditions.

Read the detailed description

This is a randomized, single-blind, placebo-controlled crossover study designed to compare acute physiological and perceptual responses to three pre-run nutritional supplements and placebo during a controlled fixed-pace 5 km treadmill run. Healthy, physically active runners will complete one screening/baseline visit and four experimental visits. Each participant will complete all four experimental conditions in randomized order and will serve as their own control. A minimum washout/recovery period of four days will separate experimental visits.

At each experimental visit, participants will receive one of four pre-run conditions: caffeine at 4 mg/kg body weight, L-citrulline at 7 g, an exogenous ketone supplement providing 11.5 g beta-hydroxybutyrate (BHB), or placebo. Study products will be provided in a standardized beverage vehicle, followed by a 45-minute waiting period before the treadmill run.

The primary physiological outcomes of interest are running economy and heart-rate drift during the fixed-pace 5 km treadmill run. Additional outcomes include oxygen consumption, carbon dioxide production, ventilation, respiratory exchange ratio, heart-rate recovery, capillary blood lactate and ketone concentrations, rating of perceived exertion, gastrointestinal symptoms, subjective fatigue, energy, focus, and participant-reported perceptions of the assigned supplement condition.

A prespecified randomly selected subgroup of up to 12 enrolled participants will use a Dexcom Stelo continuous glucose monitor during the experimental phase. CGM-derived glucose responses will be analyzed as exploratory outcomes within this subgroup only.

The study will also evaluate feasibility and tolerability, including visit completion, adverse events, supplement-related symptoms, gastrointestinal symptoms, and completeness of study measurements. The results are intended to characterize within-participant differences among the four conditions and provide preliminary data for future confirmatory studies.

02

Conditions studied

  • Exercise Physiology
  • Nutritional Supplementation

Keywords

  • Running Economy
  • Heart Rate Drift
  • Caffeine
  • L-Citrulline
  • Exogenous Ketones
  • Beta-Hydroxybutyrate
  • 5 km Running
  • Endurance Exercise
  • Nutritional Supplements
  • Indirect Calorimetry
  • Blood Lactate
  • Blood Ketones
  • Continuous Glucose Monitoring
03

In context

Lead sponsor

St. Louis University is the lead sponsor of 156 studies on the registry; 17 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-35 years
  • Healthy adult
  • Able to provide written
  • Regularly engaged in running-based aerobic training at least 3 times per week for at least 30 minutes per session during the past 3 months
  • Able to complete a 5 km run in under 30 minutes
  • Able and willing to comply with treadmill testing, fingerstick testing, dietary standardization, supplement restrictions, and pre-visit instructions
  • Participants randomly selected for the continuous glucose monitoring subgroup must also be willing to undergo Dexcom Stelo continuous glucose monitor placement and wear

Exclusion criteria

Exclusion Criteria:

  • Known cardiovascular, metabolic, pulmonary, or neurological disease that may increase the risk associated with exercise testing or materially influence study outcomes
  • Uncontrolled hypertension or another cardiovascular condition that, in the investigator's judgment, makes vigorous treadmill exercise unsafe
  • Diagnosed type 1 or type 2 diabetes mellitus or another known metabolic disease that may materially influence study outcomes
  • Pregnant, breastfeeding, or planning pregnancy during the study period
  • Current use of nitrate medications or phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil, tadalafil, or vardenafil
  • Known sensitivity or allergy to caffeine, L-citrulline, exogenous ketone/BHB salt products, or any study beverage ingredient
  • Current use of stimulant medications or other medications that may significantly influence cardiovascular, blood pressure, or metabolic responses to exercise, as determined by the investigator
  • Musculoskeletal injury or condition that limits safe treadmill running
  • Smoking or regular use of nicotine products
  • Recent illness, surgery, or hospitalization that, in the opinion of the investigators, may interfere with safe participation or study outcomes
  • Unable or unwilling to comply with study procedures or pre-visit standardization requirements
  • Running fewer than 3 times per week or otherwise not meeting the running-training inclusion criterion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Sequence 1: Caffeine-L-Citrulline-Placebo-Ketone

    Participants assigned to this randomized crossover sequence will receive caffeine, followed by L-citrulline, placebo, and exogenous ketone across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.

    Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage

  • Experimental
    Sequence 2: L-Citrulline-Ketone-Caffeine-Placebo

    Participants assigned to this randomized crossover sequence will receive L-citrulline, followed by exogenous ketone, caffeine, and placebo across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.

    Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage

  • Experimental
    Sequence 3: Ketone-Placebo-L-Citrulline-Caffeine

    Participants assigned to this randomized crossover sequence will receive exogenous ketone, followed by placebo, L-citrulline, and caffeine across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.

    Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage

  • Experimental
    Sequence 4: Placebo-Caffeine-Ketone-L-Citrulline

    Participants assigned to this randomized crossover sequence will receive placebo, followed by caffeine, exogenous ketone, and L-citrulline across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.

    Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage

Interventions

  • Dietary supplementCaffeine

    Caffeine will be administered at exactly 4 mg/kg body weight. The individualized dose will be calculated using body weight measured at the baseline visit. The commercially manufactured capsule contents will be weighed by trained study staff using a calibrated analytical balance to obtain the protocol-specified dose. Caffeine will be dispensed in the standardized study beverage and consumed 45 minutes before the fixed-pace 5 km treadmill run.

  • Dietary supplementCitrullineStudies of CitrullineCitrulline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    L-citrulline will be administered at exactly 7.0 g. The commercially manufactured pure L-citrulline powder will be weighed using a calibrated analytical balance, dispensed in the standardized study beverage, and consumed 45 minutes before the fixed-pace 5 km treadmill run.

  • Dietary supplement3-Hydroxybutyric AcidStudies of 3-Hydroxybutyric Acid3-Hydroxybutyric Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The exogenous ketone condition will consist of one 15 g serving of Nutricost Ketone BHB Salt 4-in-1 Powder, providing 11.5 g beta-hydroxybutyrate (BHB) as calcium, magnesium, sodium, and potassium BHB salts. The supplement will be dispensed in the standardized study beverage and consumed 45 minutes before the fixed-pace 5 km treadmill run.

  • Otherplacebo beverage

    The placebo will be a study-prepared beverage containing water, food-grade lime flavoring, and stevia, with no active study supplement. It will use the same standardized final volume as the active conditions and will be consumed 45 minutes before the fixed-pace 5 km treadmill run.

06

What researchers measure

Primary outcomes

  1. Running Economy (VO₂) During the Fixed-Pace 5 km Treadmill Run

    Running economy will be assessed using oxygen consumption (VO₂) measured by indirect calorimetry during standardized portions of the fixed-pace 5 km treadmill run. Within-participant running-economy responses will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits, approximately 45 minutes after supplement/placebo ingestion.

  2. Heart-Rate Drift During the Fixed-Pace 5 km Treadmill Run

    Heart-rate drift will be assessed from continuous heart-rate monitoring as the change in heart rate over the course of the fixed-pace 5 km treadmill run. Within-participant heart-rate drift will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: Throughout the fixed-pace 5 km treadmill run at each of the four experimental visits, approximately 45 minutes after supplement/placebo ingestion.

Secondary outcomes

  1. Mean Oxygen Consumption (VO₂) During the Fixed-Pace 5 km Treadmill Run

    Oxygen consumption (VO₂) will be measured continuously by indirect calorimetry and summarized as the mean body-mass-normalized VO₂ (mL/kg/min) during the fixed-pace 5 km treadmill run. Within-participant mean VO₂ will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits, beginning approximately 45 minutes after supplement/placebo ingestion.

  2. Mean Carbon Dioxide Production (VCO₂) During the Fixed-Pace 5 km Treadmill Run

    Carbon dioxide production (VCO₂) will be measured continuously by indirect calorimetry and summarized as the mean VCO₂ (L/min) during the fixed-pace 5 km treadmill run. Within-participant mean VCO₂ will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits, beginning approximately 45 minutes after supplement/placebo ingestion.

  3. Ventilation

    Pulmonary ventilation will be measured using indirect calorimetry during the fixed-pace 5 km treadmill run and compared across supplement conditions.

    Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits.

  4. Respiratory Exchange Ratio

    Respiratory exchange ratio (RER), calculated from oxygen consumption and carbon dioxide production, will be evaluated during the fixed-pace 5 km treadmill run and compared across supplement conditions.

    Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits.

  5. 1-Minute Heart-Rate Recovery After the Fixed-Pace 5 km Treadmill Run

    Heart-rate recovery will be calculated as the decrease in heart rate from the end of the fixed-pace 5 km treadmill run to 60 seconds after exercise cessation, expressed in beats per minute. Within-participant 1-minute heart-rate recovery will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: From exercise cessation to 60 seconds after completion of the fixed-pace 5 km treadmill run at each of the four experimental visits.

  6. Capillary Blood Lactate Concentration

    Capillary blood lactate concentration will be measured using finger-prick blood sampling and a point-of-care analyzer before and after exercise. Pre- to post-exercise responses will be compared across supplement conditions.

    Time frame: Immediately before and immediately after the fixed-pace 5 km treadmill run at each experimental visit.

  7. Capillary Blood Ketone Concentration

    Capillary blood ketone concentration will be measured using finger-prick blood sampling and a point-of-care analyzer before and after exercise. Pre- to post-exercise responses will be compared across supplement conditions.

    Time frame: Immediately before and immediately after the fixed-pace 5 km treadmill run at each experimental visit.

  8. Rating of Perceived Exertion

    Rating of perceived exertion will be assessed using the Borg 6-20 Rating of Perceived Exertion scale, where 6 represents no exertion and 20 represents maximal exertion; higher scores indicate greater perceived exertion.

    Time frame: During and immediately following the fixed-pace 5 km treadmill run at each experimental visit.

  9. Gastrointestinal Symptoms Severity

    Gastrointestinal symptoms, including nausea, urge to vomit, bloating, belching, and abdominal cramping, will be assessed using visual analog scales anchored from no symptoms to the worst imaginable severity for each symptom. Higher values indicate greater symptom severity. Responses will be compared across the four supplement conditions.

    Time frame: During and immediately following the fixed-pace 5 km treadmill run at each experimental visit.

  10. Subjective Fatigue

    Participant-reported fatigue will be assessed using a single-item 0-10 numeric rating scale, where 0 indicates no fatigue and 10 indicates extreme fatigue. Scores and within-visit changes will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: Immediately before supplement/placebo ingestion and immediately following the fixed-pace 5 km treadmill run at each experimental visit.

  11. Subjective Energy Level

    Participant-reported energy will be assessed using a single-item 0-10 numeric rating scale, where 0 indicates no energy at all and 10 indicates extremely high energy. Scores and within-visit changes will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: Immediately before supplement/placebo ingestion and immediately following the fixed-pace 5 km treadmill run at each experimental visit.

  12. Subjective Mental Focus

    Participant-reported mental focus will be assessed using a single-item 0-10 numeric rating scale, where 0 indicates not at all focused and 10 indicates extremely focused. Scores and within-visit changes will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: Immediately before supplement/placebo ingestion and immediately following the fixed-pace 5 km treadmill run at each experimental visit.

  13. Participant-Reported Guess of Assigned Supplement Condition

    Following each experimental visit, participants will report which supplement condition they believe they received. Responses will be summarized and compared with the actual assigned condition to evaluate participant perception of treatment assignment.

    Time frame: Immediately following completion of each experimental visit.

Other outcomes

  1. Interstitial Glucose Response During the Experimental-Visit Window in the CGM Subgroup

    Interstitial glucose will be measured continuously using continuous glucose monitoring in the prespecified randomly selected CGM subgroup. Only CGM data collected from the pre-supplement baseline through completion of the immediate post-exercise assessments at each experimental visit will be retained for analysis. Inter-visit CGM data will not be analyzed. Within-participant glucose responses will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.

    Time frame: From pre-supplement baseline through completion of the immediate post-exercise assessments at each experimental visit.

  2. Completion of All Four Experimental Visits

    Feasibility will be assessed by the number and proportion of enrolled participants who complete all four randomized experimental visits and the full four-condition crossover protocol.

    Time frame: Across each participant's approximately 4-6 weeks of study participation.

  3. Participants Experiencing Adverse Events

    Adverse events and adverse responses occurring in association with study supplementation or exercise testing will be recorded throughout study participation. The number and proportion of participants experiencing one or more adverse events will be summarized.

    Time frame: From the first study visit through completion of the final study visit, approximately 4-6 weeks per participant.

07

Study locations

1 of 1 sites recruiting
  • Saint Louis University, Allied Health Building
    St Louis, Missouri 63104, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with outside researchers. Only de-identified, aggregate study results may be used for analysis, publication, or presentation, in accordance with the approved protocol and participant privacy protections.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 2, 2026
StartEst.
Oct 2026
Primary completionEst.
Mar 2027
CompletionEst.
Aug 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854223
Responsible party
Hossein Rafiei (Assistant Professor, St. Louis University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Hossein Rafiei, PhD, RD, ACSM-CPT
Contact
hossein.rafiei@health.slu.edu
314-977-8675
Hossein Rafiei
principal investigator · St. Louis University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Caffeine · Citrulline · 3-Hydroxybutyric Acid

Start the discussion